Alopecia | Treatment Algorithms: Claims Data Analysis | US | 2022

Alopecia areata (AA) is an inflammatory autoimmune skin disease characterized by the targeting of anagen hair follicles by the host immune system, resulting in varying degrees of hair loss. While no therapies are approved for AA, topical / intralesional corticosteroids and topical or contact immunotherapy are commonly prescribed; JAK inhibitors (Pfizer’s Xeljanz, Eli Lilly’s Olumiant, Incyte’s Jakafi) may also be prescribed, albeit infrequently. As the AA current treatment landscape continues to evolve, this report offers insights from real-world claims data into prescribing trends in AA to help new players better understand current treatment practices in AA and to define the market niche for their emerging products.

QUESTIONS ANSWERED

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed AA patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed AA patients?
• How have finasteride and corticosteroids been integrated into the treatment algorithm, and what is their source of business? To what extent are JAK inhibitors (e.g., Pfizer’s Xeljanz) used off-label for AA?
• What percentage of AA patients receive drug therapy within one year of diagnosis and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of AA patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

SOLUTION ENHANCEMENT

The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and quarterly data refreshes.

Markets covered: United States

Key drugs: Anthralin, minoxidil, corticosteroids, contact allergens, pimecrolimus, finasteride, methotrexate, cyclosporine A, Jakafi, Olumiant, tacrolimus (topical), Xeljanz